Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class v lupus nephritis

Kidney International

Volumn 77, Issue 2, 2010, Pages 152-160

  Radhakrishnan, Jai ^a   Moutzouris, Dimitrios Anestis ^b   Ginzler, Ellen M ^c   Solomons, Neil ^d   Siempos, Ilias I ^e   Appel, Gerald B ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b EVANGELISMOS HOSPITAL   (Greece)

^c SUNY Downstate Medical Center   (United States)

^d Vifor (International) Inc   (Switzerland)

^e ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

Immunosuppression; Lupus nephritis; Nephrotic syndrome

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GENITAL HERPES; HERPES ZOSTER; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAIL TINEA; NAUSEA; NEPHROTIC SYNDROME; ORAL CANDIDA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING;

ADOLESCENT; ADULT; CREATININE; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PROTEINURIA; REMISSION INDUCTION; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 73349129039     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.412     Document Type: Article

References (33)

1. Appel A, Appel G. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 2009; 5: 132-142.
2. Austin HA, Illei GG. Membranous lupus nephritis. Lupus 2005; 14: 65-71.
3. D'Agati V, Appel G. Lupus nephritis: pathology and pathogenesis. In: DJ Wallace, BH Hahn (eds). Dubois' Lupus Erythematosus. Lippincott Williams: Wilkins, 2007.
4. Donadio Jr JV, Burgess JH, Holley KE. Membranous lupus nephro-pathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56: 527-536.
5. Baldwin DS, Gluck MC, Lowenstein J et al. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med 1977; 62: 12-30.
6. Appel GB, Silva FG, Pirani CL et al. Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371-410.
7. Austin 3rd HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
8. Chan TM, Li FK, Hao WK et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-551.
9. Mok CC, Ying KY, Lau CS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43: 269-276.
10. Hallegua D, Wallace DJ, Metzger AL et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000; 9: 241-251.
11. Radhakrishnan J, Kunis CL, D'Agati V et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
12. Hu W, Liu Z, Shen S et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (Engl) 2003; 116: 1827-1830.
13. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
14. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
15. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
16. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
17. Spetie DN, Tang Y, Rovin BH et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66: 2411-2415.
18. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
19. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
20. Pasquali S, Banfi G, Zucchelli A et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-182.
21. Pasquali JL. Acute lupus erythematosus disseminatus. Diagnosis, development, prognosis, principles of the treatment. Rev Prat 1991; 41: 945-948.
22. Austin 3rd HA, Illei GG, Braun MJ et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20: 901-911.
23. Appel G, Waldman M, Radhakrishnan J. New approaches to the treatment of glomerular disease. Kidney Int 2006; 70: S45-S50.
24. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006; 70: 1403-1412.
25. Hu W, Liu Z, Chen H et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705-709.
26. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510.
27. Contreras G, Tozman E, Nahar N et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14(Suppl 1): s33-s38.
28. Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44: 1317-1321.
29. Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7: 299-305.
30. Kapitsinou PP, Boletis JN, Skopouli FN et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004; 43: 377-380.
31. Dooley MA, Hogan S, Jennette C et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
32. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
33. Zumbo B, Hubley A. A note in misconceptions concerning prospective and retrospective power. The Statistician 1998; 47: 385-388.